Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Phone therapy boosts inhaler use in anxious asthma patients

NCT ID NCT06732141

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether weekly phone calls with education, relaxation techniques, and motivational interviewing can help adults with asthma who are anxious about using their inhalers. 216 participants will be split into two groups: one gets the extra phone support, the other gets standard care. The goal is to see if the calls improve inhaler use, reduce anxiety, and lead to better asthma control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 216 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2024

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age Requirement: Participants must be aged 18 to 80 years, ensuring they are adults capable of making decisions and responding effectively to interventions. 2. Diagnosed Asthma: 1. Diagnosis must meet the criteria of the Global Initiative for Asthma (GINA) or the American Academy of Asthma guidelines, with at least one confirmed diagnosis by a specialist in the past six months. 2. Asthma severity must range from mild to moderate persistent, in the chronic management phase, excluding patients in acute exacerbation phases for clearer evaluation of adherence and intervention effects. 3. ICS Treatment History: 1. Participants must have been on inhaled corticosteroid (ICS) therapy for at least six months, ensuring sufficient treatment history for adherence and effect evaluation. 2. No major changes to asthma control medication regimen in the past six months, ensuring adherence and intervention outcomes are not confounded by treatment changes. 4. Poor Medication Adherence: Identified using the Medication Adherence Report Scale (MARS-10), with an average score \<4.5, indicating suboptimal adherence. 5. Presence of Anxiety Symptoms: 1. Confirmed through the Hamilton Anxiety Rating Scale (HAMA), with a score ≥14, indicating clinically significant anxiety. 2. Anxiety symptoms must be related to asthma treatment, particularly concerns about ICS side effects or long-term use, ensuring the psychological intervention targets relevant issues. 6. Ability to Communicate by Phone: Participants must have stable access to a phone and be willing to engage in telephone-based psychological interventions. 7. Stable Health Condition: Asthma status must be stable, with no acute exacerbations or significant changes in the past month. Exclusion Criteria: 1. Severe Psychiatric or Cognitive Disorders: 1. Diagnosis of major psychiatric disorders, such as major depressive disorder, bipolar disorder, schizophrenia, or other severe mental illnesses within the past six months, based on DSM-5 criteria. 2. Presence of cognitive impairments or neurological conditions, such as dementia or post-stroke complications, that may affect comprehension or adherence to the intervention. 3. Current psychiatric treatment involving antipsychotics, antidepressants, or sedatives that could interfere with the intervention's outcomes. 2. Substance Abuse or Dependence: History of alcohol or drug abuse within the past six months, including but not limited to opioids, benzodiazepines, or illicit substances. 3. Severe Comorbidities: 1. Uncontrolled respiratory or cardiovascular conditions, such as chronic obstructive pulmonary disease (COPD), bronchiectasis, interstitial lung disease, heart failure, or uncontrolled hypertension, that could significantly impact asthma control and overall health. 2. Chronic diseases requiring long-term systemic corticosteroid therapy, such as rheumatic or autoimmune diseases, that may interfere with ICS treatment and study outcomes. 4. Pregnancy or Lactation: Pregnant or breastfeeding women are excluded due to the unclear risks of ICS treatment and anxiety management interventions in these populations. 5. Allergic Bronchopulmonary Aspergillosis (ABPA) or Related Conditions: Diagnosed ABPA or other respiratory diseases with mechanisms distinct from asthma, which could confound the assessment of ICS treatment effects. 6. Participation in Other Interventional Clinical Trials: Participation in another interventional clinical trial within the past three months, particularly those involving respiratory diseases or medication adherence management, to avoid confounding effects on outcomes. 7. Incompatibility with Telephone-Based Interventions: Inability to reliably receive or engage in telephone-based psychological interventions due to hearing impairments, communication barriers, or other reasons. 8. Adverse Reactions to Psychological Interventions: Documented refusal of or adverse reactions to psychological interventions, such as phone-based relaxation or motivational interviewing, that could affect the feasibility and effectiveness of the study. 9. History of Major Surgery or Hospitalization: History of major surgery or hospitalization (unrelated to asthma) within the past six months that might impact current health status and introduce bias into the study outcomes.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asthma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Anhui Chest Hospital

    RECRUITING

    Hefei, China

  • Haishu District People's Hospital

    NOT_YET_RECRUITING

    Ningbo, China

  • Jingzhou Central Hospital

    RECRUITING

    Jingzhou, China

  • Ningbo Medical Center Lihuili Hospital

    RECRUITING

    Ningbo, China

  • Ninghai County First Hospital

    RECRUITING

    Ninghai, China

  • Qianhu Hospital

    RECRUITING

    Ningbo, China

  • Second Affiliated Hospital of Harbin Medical University

    RECRUITING

    Harbin, China

  • Taizhou Central Hospital

    NOT_YET_RECRUITING

    Taizhou, China

  • The First Affiliated Hospital of Anhui Medical University

    RECRUITING

    Hefei, China

  • The First Affiliated Hospital of Ningbo University

    RECRUITING

    Ningbo, China

  • The Second Affiliated Hospital of Anhui Medical University

    RECRUITING

    Hefei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.